Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12934504 | 0.90 | RAB9A (0.44) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL8226239 | 0.90 | P2RX3 (0.44) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL29716162 | 0.86 | P2RX3 (0.46) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL13395392 | 0.86 | P2RX3 (0.46) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL29992438 | 0.85 | P2RX3 (0.44) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL15987117 | 0.85 | P2RX3 (0.48) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL6864274 | 0.85 | P2RX3 (0.48) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL29991596 | 0.85 | P2RX3 (0.48) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL14730353 | 0.85 | P2RX3 (0.48) | P2RX3RAB9AKDM4ENPC1L3MBTL1 | |
| SCHEMBL22764049 | 0.83 | P2RX3 (0.44) | P2RX3RAB9AKDM4ENPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970335-B1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014145095-A1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | P2RX3 3516/4885RAB9A 2463/4885KDM4E 2747/4885 |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | P2RX3 3516/4885RAB9A 2463/4885KDM4E 2747/4885 |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | P2RX3 3817/4885RAB9A 692/4885KDM4E 2417/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | P2RX3 3658/4885RAB9A 1069/4885KDM4E 2585/4885 |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | P2RX3 3516/4885RAB9A 2463/4885KDM4E 2747/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | P2RX3 3658/4885RAB9A 1069/4885KDM4E 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.